Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Agnieszka Wierzbowska, MDPhD, Agnieszka Pluta, MDPhD, Marta Antonina Libura, MDPhD, Anna Czyz, MDPhD, Sebastian Giebel, MDPhD, Piotr Stelmach, MDPhD, Magdalena Czemerska, MDPhD, Anna Kopinska, MD, Krzysztof Wozniczka, MDPhD, Grzegorz Helbig, MDPhD, Karol Wojcik, MD, Malgorzata Razny, MDPhD, Marta Sobas, MDPhD, Tomasz Wrobel, MDPhD, Andrzej Szczepaniak, MDPhD, Lidia Gil, MDPhD, Alicja Sadowska-Klasa, MD, Jan Zaucha, MDPhD, Tomasz Gromek, MDPhD, Marek Hus, MDPhD, Edyta Cichocka, MDPhD, Janusz Halka, MDPhD, Elzbieta Patkowska, Jolanta Wozniak, PhD, Agata Obara, MD, Beata Blajer-Olszewska, MD, Katarzyna Dulik, MD, Jerzy Holowiecki, MDPhD, Michal Soin, M.Sc., Tadeusz Robak, MDPhD, Nicole M. Cruz, MD, Nuria Mencia-Trinchant, PhD, Pinkal Desai, MDMPH, Sangmin Lee, MD, Michael B. Samuel, MD, Justin D. Kaner, MD, Ellen Ritchie, MD, Monica L. Guzman, PhD, Gail J. Roboz, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-140694

Published: 2020

Journal Articles

A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis

Naveen Pemmaraju, MD, Vikas Gupta, MD FRCP, FRCPath, Haris Ali, MD, Abdulraheem Yacoub, MD, Eunice S. Wang, MD, Sangmin Lee, MD, Gary J. Schiller, MD, Christopher Brooks, PhD, Nicole Rupprecht, MS, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Moshe Talpaz, MD, Minakshi S. Taparia, MBBS, Tariq I. Mughal, MD FRCP, Srdan Verstovsek, MD PhD, Joseph D. Khoury, MD, Mrinal M. Patnaik, MDMBBS

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-137572

Published: 2020

Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 674.

https://doi.org/10.1182/blood-2019-124360

Published: 2019

Journal Articles

Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms

Pinkal Desai, MDMPH, Niamh Savage, BA, Spencer Krichevsky, BS, Tania Curcio, Sangmin Lee, MD, Michael B. Samuel, MD, Ellen K. Ritchie, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 1666.

https://doi.org/10.1182/blood-2019-127663

Published: 2019

Journal Articles

Changes in Gut Microbial Diversity and Correlations with Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Receiving Intensive Chemotherapy

Sangmin Lee, MD, Ellen K. Ritchie, MD, Sumaiya Miah, Caroline Andy, Tania Curcio, Finola Goudy, Michael Hovan, Claire Douglass, Pinkal Desai, MDMPH, Michael B. Samuel, MD, Gail J. Roboz, MD, Michael Satlin, MD, M.S.

Blood (2019) 134 (Supplement_1): 1336.

https://doi.org/10.1182/blood-2019-125441

Published: 2019

Journal Articles

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Sangmin Lee, MD, Bhavana Bhatnagar, DO, Sanjay R Mohan, MD MSCI, William T. Senapedis, Jr., Erkan Baloglu, PhD, Hongwei Wang, MD, Jatin J. Shah, MD, Sharon Shacham, PhD MBA, Michael G. Kauffman, MD PhD

Blood (2019) 134 (Supplement_1): 2997.

https://doi.org/10.1182/blood-2019-124136

Published: 2019

Journal Articles

Antecedent Clonal Hematopoesis and Risk of and Mortality after Solid and Hematological Malignancies: Analyses from the Women's Health Initiative Study

Pinkal Desai, MDMPH, Samuel Handelman, PhD, Alan Wu, MPH, Paul J Christos, Dr.P.H., M.S., Sangmin Lee, MD, Michael B. Samuel, MD, Ellen K. Ritchie, MD, Monica L. Guzman, PhD, Rebecca Jackson, Duane C. Hassane, PhD, Joann Manson, Alexander Reiner, MD, Michael S. Simon, MDMPH, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 1199.

https://doi.org/10.1182/blood-2019-131862

Published: 2019

Journal Articles

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Blood (2019) 134 (Supplement_1): 558.

https://doi.org/10.1182/blood-2019-131217

Published: 2019

Journal Articles

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

Blood (2019) 134 (Supplement_1): 231.

https://doi.org/10.1182/blood-2019-123920

Published: 2019

Journal Articles

PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71

Justin D. Kaner, MD, Montreh Tavakkoli, MA,MD, Lisa Toudic, Brett M. Stevens, PhD, Craig T Jordan, PhD, Tony Taldone, PhD, Gabriela Chiosis, PhD, Ellen K. Ritchie, MD, Pinkal Desai, MDMPH, Michael B. Samuel, MD, Sangmin Lee, MD, Gail J. Roboz, MD, Monica L. Guzman, PhD

Blood (2019) 134 (Supplement_1): 3935.

https://doi.org/10.1182/blood-2019-128276

Published: 2019

Journal Articles

CPX-351 As First Intensive Therapy for Elderly Patients with AML

Ellen K. Ritchie, MD, Sumaiya K. Miah, BA, Sangmin Lee, MD, Tania Curcio, Pinkal Desai, MDMPH, Jeffrey Ball, MD, Michael B. Samuel, MD, Gail J. Roboz, MD

Blood (2019) 134 (Supplement_1): 3858.

https://doi.org/10.1182/blood-2019-130263

Published: 2019

Journal Articles

Acute Myeloid Leukemia (AML) with Somatic Mutations in PTPN11 Is Associated with Treatment Resistance and Poor Overall Survival

Justin D. Kaner, MD, Nuria Mencia-Trinchant, PhD, Ariel Schaap, MD, Gail J. Roboz, MD, Sangmin Lee, MD, Pinkal Desai, MD MPH, Michael Samuel, MD, Spencer Krichevsky, BS, Idongessit Udoyen, Duane C. Hassane, PhD, Monica L. Guzman, PhD, Ellen K. Ritchie, MD

Blood (2018) 132 (Supplement 1): 2760.

https://doi.org/10.1182/blood-2018-99-110319

Published: 2018

Journal Articles

Correlations between Pre-Transplant Treatment and Bone Marrow Response with Post-Transplant Outcomes in Patients with Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation

Pinkal Desai, MD MPH, Alfadel Alshaibani, MD, Xian Wu, MPH, Sangmin Lee, MD, Jingmei Hsu, MD, Ellen K. Ritchie, MD, Michael Samuel, MD, Sebastian A. Mayer, MD, Adrienne A. Phillips, MD MPH, Usama Gergis, MD M.B.A, Tsiporah B. Shore, MD, Koen Van Besien, MD PhD, Gail J. Roboz, MD

Blood (2018) 132 (Supplement 1): 4391.

https://doi.org/10.1182/blood-2018-99-118366

Published: 2018

Journal Articles

Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?

Sangmin Lee, MD, Jingmei Hsu, MD, Yassine Tahri, MD, Zhengming Chen, PhD MPH, MS, Tsiporah B. Shore, MD, Ellen K. Ritchie, MD, Usama Gergis, MD M.B.A, Pinkal Desai, MD MPH, Sebastian A. Mayer, MD, Michael Samuel, MD, Adrienne A. Phillips, MD MPH, Melissa M. Cushing, MD, Gail J. Roboz, MD, Koen Van Besien, MD PhD

Blood (2018) 132 (Supplement 1): 2172.

https://doi.org/10.1182/blood-2018-99-119946

Published: 2018

Journal Articles

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis

Naveen Pemmaraju, MD, Vikas Gupta, MD FRCP, FRCPath, Gary J. Schiller, MD, Sangmin Lee, MD, Abdulraheem Yacoub, MD, Haris Ali, MD, Moshe Talpaz, MD, Megan Sardone, Halyna Wysowskyj, Shay Shemesh, Janice Chen, PhD, Arturo Olguin, Christopher Brooks, PhD, Vanessa Dunn, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD PhD, Joseph David Khoury, MD, Mrinal M. Patnaik, MDMBBS

Blood (2018) 132 (Supplement 1): 1773.

https://doi.org/10.1182/blood-2018-99-119201

Published: 2018

Journal Articles

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)

Mrinal M. Patnaik, MD MBBS, Haris Ali, MD, Vikas Gupta, MD FRCP, FRCPath, Gary J. Schiller, MD, Sangmin Lee, MD, Abdulraheem Yacoub, MD, Moshe Talpaz, MD, Megan Sardone, Halyna Wysowskyj, Shay Shemesh, Janice Chen, PhD, Arturo Olguin, Christopher Brooks, PhD, Vanessa Dunn, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Srdan Verstovsek, MD PhD, Joseph David Khoury, MD, Naveen Pemmaraju, MD

Blood (2018) 132 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2018-99-119302

Published: 2018

Journal Articles

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Blood (2018) 132 (Supplement 1): 1452.

https://doi.org/10.1182/blood-2018-99-114126

Published: 2018

Journal Articles

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1 m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Justin Watts, MD, Maria R. Baer, MD, Jay Yang, MD, Shira Dinner, MD, Sangmin Lee, MD, Karen Seiter, MD, Thomas Prebet, MD PhD, Gary J. Schiller, MD, Paul Brent Ferrell, Jr., MD, Kim-Hien Dao, DO, PhD, Hagop M. Kantarjian, MD, Patrick Kelly, MD, Ping Li, PhD, Jennifer Sweeney, Courtney Watson, Hesham Mohamed, MD, Jorge E. Cortes, MD

Blood (2018) 132 (Supplement 1): 1453.

https://doi.org/10.1182/blood-2018-99-114263

Published: 2018

Journal Articles

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Peter Westervelt, MDPhD, Gail J. Roboz, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Sangmin Lee, MD, Michael P. Rettig, PhD, Tae H. Han, PhD, Jeanmarie Guenot, PhD, Eric J. Feldman, MD, John F. DiPersio, MD PhD

Blood (2018) 132 (Supplement 1): 1455.

https://doi.org/10.1182/blood-2018-99-111529

Published: 2018

Journal Articles

Acute Myeloid Leukemia (AML) Patients Demonstrate Increased Prevalence of AML-Defining Mutations in Peripheral Blood Years Prior to the Development of Overt Leukemia: A Case-Control Study

Pinkal Desai, MDMPH, Nuria Mencia-Trinchant, PhD, Savenkov Oleksandr, PhD, Michael S. Simon, MDMPH, Sangmin Lee, MD, Ellen K Ritchie, MD, Monica L. Guzman, PhD, Karla V Ballman, PhD, Gail J. Roboz, MD, Duane C. Hassane, PhD

Blood (2017) 130 (Supplement 1): 408.

https://doi.org/10.1182/blood.V130.Suppl_1.408.408

Published: 2017

NARROW

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

A Multicenter Phase 1/2 Clinical Trial of Tagraxofusp, a CD123-Targeted Therapy, in Patients with Poor-Risk Primary and Secondary Myelofibrosis

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms

Changes in Gut Microbial Diversity and Correlations with Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Receiving Intensive Chemotherapy

Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome

Antecedent Clonal Hematopoesis and Risk of and Mortality after Solid and Hematological Malignancies: Analyses from the Women's Health Initiative Study

Results from a Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate, or High Risk, Relapsed/Refractory Myelofibrosis

Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients with Acute Myeloid Leukemia Treated in a Phase 1 Dose Escalation and Expansion Study

PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71

CPX-351 As First Intensive Therapy for Elderly Patients with AML

Acute Myeloid Leukemia (AML) with Somatic Mutations in PTPN11 Is Associated with Treatment Resistance and Poor Overall Survival

Correlations between Pre-Transplant Treatment and Bone Marrow Response with Post-Transplant Outcomes in Patients with Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation

Does Presence of Persistent Molecular Mutations Matter in AML Patients Undergoing Allogeneic Stem Cell Transplant?

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis

Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML)

FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study

Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1 m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2x2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML) Patients Demonstrate Increased Prevalence of AML-Defining Mutations in Peripheral Blood Years Prior to the Development of Overt Leukemia: A Case-Control Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only